Originally Aired: August 11, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

The world of precision medicine is gaining more focus, but challenges in optimization and scalability remain especially when developing autologous therapies. There are a few technologies out there looking to solve these problems for researchers. In this GEN webinar, learn how Lonza’s Cocoon™ cell therapy manufacturing platform and IsoPlexis’ IsoLight™ single-cell proteomics system can be used together to advance the future of cancer immunotherapy. Each is a closed, fully automated benchtop system that does not require numerous personnel and extensive training to run. Together, these next-generation platforms allow for decentralized manufacturing of novel cell therapies and a solution for complete functional characterization of each cell in a cell therapy product, to ensure correlative functional potency of the manufactured cell product. Improved end-to-end automation minimizes the need for human involvement in numerous steps, and the single-cell proteomics system provides functional phenotyping to better characterize the cell therapy product from heterogeneous cell populations.

During this event, our presenters will discuss the future of cell therapy manufacturing with the Cocoon, an automated, highly flexible cell therapy manufacturing platform, and how the automated functional proteomics analysis IsoLight platform provides predictive quality analytics for the manufacturing and bioprocessing of cell therapy products at every stage of the process.

A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.

 

Produced with support from:

 

 

Matthew Hewitt, PhD
Head of R&D (a.i.) and
Clinical Development,
Personalized Medicine
Lonza

Stacey Willard, PhD
Director of Product Management
IsoPlexis